The ARMC8 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human HT29 colorectal adenocarcinoma line, designed for loss-of-function studies of the ARMC8 gene. This heterogeneous knockout model circumvents clonal selection, thereby facilitating unbiased functional analysis in a colorectal cancer context. The cells are suitable for investigating ARMC8??s role in ubiquitin-mediated cell cycle control and for broader cancer biology applications.
HT29 is a widely characterized human colorectal adenocarcinoma epithelial cell line isolated from a primary tumor. It harbors established oncogenic mutations, including in APC, TP53, and BRAF (V600E), and displays reliable tumorigenic and metastatic properties in xenograft models. The line??s epithelial origin and well-documented growth and drug-response profiles make it an ideal host for interrogating gene function in colorectal cancer.
ARMC8 encodes an essential subunit of the CTLH E3 ubiquitin ligase complex, which also includes MAEA, RMND5A, and GID4. The CTLH complex catalyzes the transfer of ubiquitin moieties to substrate proteins, directing them to the 26S proteasome for degradation. Through this activity, ARMC8 participates in the regulation of cell cycle transitions and proliferative signaling. Its interactions with MAEA and RMND5A are critical for complex stability and catalytic function, placing ARMC8 within a ubiquitin signaling network that governs cell division.
Knockout of ARMC8 in HT29 cells enables direct interrogation of CTLH complex contributions to colorectal cancer phenotypes. As aberrant ubiquitination and cell cycle dysregulation are hallmarks of colorectal tumors, this model permits quantitative assessment of changes in proliferation, apoptosis, and cell cycle distribution. Comparative studies with parental HT29 cells can reveal CTLH-dependent proteomic alterations and identify synthetic lethal interactions, supporting therapeutic target evaluation.
These ARMC8 knockout polyclonal cells are compatible with a range of research assays, including Western blotting for ARMC8 and ubiquitin profiling, MTT or resazurin-based proliferation assays, flow cytometry for cell cycle phase analysis, and Annexin V/PI apoptosis detection. Co-immunoprecipitation can examine CTLH complex assembly with MAEA, RMND5A, and GID4, while in vitro ubiquitination assays probe substrate modification. The cells also serve as a tool for drug target validation and high-throughput screening. For additional details or technical support, please contact Ascent Research.
